Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 14, 2025Oncology and TherapyOpen Access

Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

TMTalha MunirNMNicolás Martínez‐CalleSXSheng Xu

Discussion

Loading...

Member takes

Overview

Indirect comparison demonstrates zanubrutinib improves progression-free survival and safety profile in chronic lymphocytic leukemia.

Key Points

  • Zanubrutinib reveals a significant PFS benefit compared with venetoclax plus obinutuzumab, with a hazard ratio of 0.66.
  • Patients receiving zanubrutinib showed a higher probability of prolonged PFS at 60 months, achieving 73.9% versus 63% for venetoclax plus obinutuzumab.
  • Matching-adjusted indirect comparison analysis utilized data from SEQUOIA for zanubrutinib and CLL14 for venetoclax plus obinutuzumab.
  • Zanubrutinib treatment resulted in lower rates of selected adverse events compared to venetoclax plus obinutuzumab, suggesting a favorable safety profile.

Cite This Study

Munir et al. (2025) studied this question.

synapsesocial.com/papers/68d44f7b31b076d99fa56cechttps://doi.org/10.1007/s40487-025-00380-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A matching-adjusted indirect comparison (MAIC) of zanubrutinib vs venetoclax + ibrutinib in treatment-naive chronic lymphocytic leukemia (CLL)2025
  2. 2Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up2026
  3. 3Zanubrutinib versus fludarabine, cyclophosphamide and rituximab in fit, treatment-naïve patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison2026
  4. 4Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study2026
  5. 5An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL2024 · 8 citations